MENA Region Pharma Market 2024: The Middle East and Africa ( MENA Region) pharmaceutical sector continues to demonstrate solid momentum in 2024, achieving a total market value of $32.2 billion with 10.2% year-on-year growth . IQVIA’s latest MAT Q2 2024 insights reveal that most  MENA Region countries have maintained a positive trajectory despite global challenges, driven by expanding retail channels, growing therapeutic segments, and a surge in both multinational and regional players.

 💊 Retail Channel Dominates  MENA Region Growth

Retail remains the primary growth engine of the  MENA Region pharma market, accounting for 69.1% of total value sales . and growing by 12.2% PPG. The hospital channel also showed stable performance with 6.0% value growth .

•  Retail value share: $22.2B
• Hospital value share: $10.0B
• Overall growth: +10.2% value, -0.8% volume

This performance reflects the region’s expanding private healthcare infrastructure and increased accessibility of prescription and OTC drugs through pharmacies.

 🏭 Regional Dynamics: Country Highlights

Saudi Arabia (KSA)

•  Largest  MENA Region market: $11.8B, up 8.1% PPG
• Hospital share: 48% of sales
• Sanofi leads the market; Jamjoom Pharma is the fastest-growing local player (+22.3%).

 United Arab Emirates

• Second-largest market: $4.4B, up 18.2% PPG
• Strongest TA growth in Type II Antidiabetics (+67.7%)
• Eli Lilly recorded outstanding growth (+98.2%), fueled by Mounjaro and Taltz.

 Egypt

• Market decline: –4.2% PPG (value)
• Retail dominates with 80.6% share
• Systemic Antibacterials lead (10.7% share), while *Anti-Ulcerants* grow fastest (+3.4%).

South Africa

• Modest growth:+0.4% PPG
• Retail remains dominant (81.9%)
• Adcock Ingram leads, while Novo Nordisk grows fastest (+8.9%).

 📈 Local vs. Multinational Performance

Local and regional players continue to strengthen their position:

Local/Regional companies grew 9.1% in value, led by Egypt, UAE, and Tunisia.

Multinational companies (MNCs) still command 60% of total value, with notable growth in KSA and UAE.

Key regional champions — Hikma, Tabuk, and SPIMACO — collectively generate $2.3B, representing 17.9% of local company sales.

 Top Therapeutic Areas in  MENA Region

1. Alimentary Tract & Metabolism – 20% of total sales, +17% PPG
2. Dominant in KSA (36.8% of this TA)
3. Antineoplastics & Immunomodulators – +17.2% PPG, driven by UAE (+30.6%)
4. Nervous System – +8% CAGR
5. Cardiovascular System – +6% CAGR
6. Respiratory System – +8% CAGR

The clear focus on metabolic and oncology therapies signals a regional shift toward chronic disease management and biologics.

🔍 Market Outlook to 2028

According to IQVIA’s Market Prognosis (May 2024):

•  The global pharma market is forecasted to hit $2.32 trillion by 2028 (7.9% CAGR).
•  MENA Region’s pharma business will grow to $64.1 billion, expanding at ~6% CAGR.
• Key growth drivers: lifestyle diseases, biosimilars, and digital health integration.

IQVIA Spotlight: New Market Offerings :

IQVIA continues to enhance its analytical coverage across the ME region:

• Iraq Retail Audit: first full quarterly audit of Iraq’s pharma market.
• Egypt Switch Tracker (ESWT): real-time tracking of pharmacy switching behavior.
• Jordan Consumer Sell-Out Data: digital capture of pharmacy-to-patient transactions.
• Omnichannel Engagement Programs: “Phygital” marketing strategies in KSA increasing HCP engagement rates to 23%.

 🏁 Conclusion

The  MENA Region pharmaceutical market is entering a transformative growth phase . fueled by strong retail expansion. local manufacturing capacity, and strategic multinational partnerships.

As we move toward 2028 . success in the region will depend on how companies leverage data-driven insights, regulatory adaptation, and hybrid engagement models.

• Follow more of our services here

  Explore Services
  +971 56 636 0153
  info@senuconsult.com

  Have Any Questions? Contact us here
  +971566360153 or
  info@senuconsult.com